Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
O'Rourke CJ, Salati M, Rae C, Carpino G, Leslie H, Pea A, Prete MG, Bonetti LR, Amato F, Montal R, Upstill-Goddard R, Nixon C, Sanchon-Sanchez P, Kunderfranco P, Sia D, Gaudio E, Overi D, Cascinu S, Hogdall D, Pugh S, Domingo E, Primrose JN, Bridgewater J, Spallanzani A, Gelsomino F, Llovet JM, Calvisi DF, Boulter L, Caputo F, Lleo A, Jamieson NB, Luppi G, Dominici M, Andersen JB, Braconi C. O'Rourke CJ, et al. Gut. 2024 Feb 23;73(3):496-508. doi: 10.1136/gutjnl-2023-330748. Gut. 2024. PMID: 37758326 Free PMC article.
Epigenome dysregulation in cholangiocarcinoma.
O'Rourke CJ, Munoz-Garrido P, Aguayo EL, Andersen JB. O'Rourke CJ, et al. Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1423-1434. doi: 10.1016/j.bbadis.2017.06.014. Epub 2017 Jun 20. Biochim Biophys Acta Mol Basis Dis. 2018. PMID: 28645654 Free article. Review.
Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
Lozano E, Macias RIR, Monte MJ, Asensio M, Del Carmen S, Sanchez-Vicente L, Alonso-Peña M, Al-Abdulla R, Munoz-Garrido P, Satriano L, O'Rourke CJ, Banales JM, Avila MA, Martinez-Chantar ML, Andersen JB, Briz O, Marin JJG. Lozano E, et al. Hepatology. 2019 Oct;70(4):1246-1261. doi: 10.1002/hep.30656. Epub 2019 May 20. Hepatology. 2019. PMID: 30972782
Epigenome Remodeling in Cholangiocarcinoma.
O'Rourke CJ, Lafuente-Barquero J, Andersen JB. O'Rourke CJ, et al. Trends Cancer. 2019 Jun;5(6):335-350. doi: 10.1016/j.trecan.2019.05.002. Epub 2019 Jun 4. Trends Cancer. 2019. PMID: 31208696 Review.
Molecular Targets in Cholangiocarcinoma.
O'Rourke CJ, Munoz-Garrido P, Andersen JB. O'Rourke CJ, et al. Hepatology. 2021 Jan;73 Suppl 1:62-74. doi: 10.1002/hep.31278. Epub 2020 Dec 3. Hepatology. 2021. PMID: 32304327 Review.
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
Esparza-Baquer A, Labiano I, Sharif O, Agirre-Lizaso A, Oakley F, Rodrigues PM, Zhuravleva E, O'Rourke CJ, Hijona E, Jimenez-Agüero R, Riaño I, Landa A, La Casta A, Zaki MYW, Munoz-Garrido P, Azkargorta M, Elortza F, Vogel A, Schabbauer G, Aspichueta P, Andersen JB, Knapp S, Mann DA, Bujanda L, Banales JM, Perugorria MJ. Esparza-Baquer A, et al. Gut. 2021 Jul;70(7):1345-1361. doi: 10.1136/gutjnl-2019-319227. Epub 2020 Sep 9. Gut. 2021. PMID: 32907830 Free PMC article.
Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.
Høgdall D, O'Rourke CJ, Dehlendorff C, Larsen OF, Jensen LH, Johansen AZ, Dang H, Factor VM, Grunnet M, Mau-Sørensen M, Oliveira DVNP, Linnemann D, Boisen MK, Wang XW, Johansen JS, Andersen JB. Høgdall D, et al. Clin Cancer Res. 2020 Nov 1;26(21):5655-5667. doi: 10.1158/1078-0432.CCR-19-2700. Epub 2020 Sep 15. Clin Cancer Res. 2020. PMID: 32933994 Free PMC article.
36 results